These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 10669190)

  • 21. Rationale for the use of hydroxyurea as an anti-human immunodeficiency virus drug.
    Lori F; Lisziewicz J
    Clin Infect Dis; 2000 Jun; 30 Suppl 2():S193-7. PubMed ID: 10860905
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Predictors of plasma human immunodeficiency virus type 1 RNA control after discontinuation of highly active antiretroviral therapy initiated at acute infection combined with structured treatment interruptions and immune-based therapies.
    Lafeuillade A; Poggi C; Hittinger G; Counillon E; Emilie D
    J Infect Dis; 2003 Nov; 188(10):1426-32. PubMed ID: 14624367
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Use of hydroxyurea in psoriasis.
    Smith CH
    Clin Exp Dermatol; 1999 Jan; 24(1):2-6. PubMed ID: 10233638
    [TBL] [Abstract][Full Text] [Related]  

  • 24. New uses for old drugs in HIV infection: the role of hydroxyurea, cyclosporin and thalidomide.
    Ravot E; Lisziewicz J; Lori F
    Drugs; 1999 Dec; 58(6):953-63. PubMed ID: 10651384
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The HYDILE trial: efficacy and tolerance of a quadruple combination of reverse transcriptase inhibitors versus the same regimen plus hydroxyurea or hydroxyurea and interleukin-2 in HIV-infected patients failing protease inhibitor-based combinations.
    Lafeuillade A; Hittinger G; Chadapaud S; Maillefet S; Rieu A; Poggi C
    HIV Clin Trials; 2002; 3(4):263-71. PubMed ID: 12187499
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Seminal reservoirs during an HIV type 1 eradication trial.
    Nunnari G; Leto D; Sullivan J; Xu Y; Mehlman KE; Kulkosky J; Pomerantz RJ
    AIDS Res Hum Retroviruses; 2005 Sep; 21(9):768-75. PubMed ID: 16218800
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Safety of hydroxyurea in the treatment of HIV infection.
    Lori F; Kelly LM; Foli A; Lisziewicz J
    Expert Opin Drug Saf; 2004 Jul; 3(4):279-88. PubMed ID: 15268646
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Immune restoration by combination of a cytostatic drug (hydroxyurea) and anti-HIV drugs (didanosine and indinavir).
    Lori F; Jessen H; Lieberman J; Clerici M; Tinelli C; Lisziewicz J
    AIDS Res Hum Retroviruses; 1999 May; 15(7):619-24. PubMed ID: 10331440
    [TBL] [Abstract][Full Text] [Related]  

  • 29. What they say about complementary drugs.
    Posit Aware; 1999; 10(1):45. PubMed ID: 11366524
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Short-term anti-HIV activity of the combination of didanosine and hydroxyurea.
    Clotet B; Ruiz L; Cabrera C; Ibáñez A; Cañadas MP; Sirera G; Romeu J; Vila J
    Antivir Ther; 1996 Aug; 1(3):189-93. PubMed ID: 11322253
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Hydroxyurea for HIV infection.
    Zachary KC; Davis B
    AIDS Clin Care; 1998 Apr; 10(4):25-6, 32. PubMed ID: 11365149
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Hydroxyurea.
    Gortner C
    BETA; 1998 Oct; ():7. PubMed ID: 11365996
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Hydroxyurea.
    Bowers M
    BETA; 1997 Mar; ():9-11. PubMed ID: 11364534
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Advantages of HIV treatment with Hydrea (Hydroxyurea).
    Baker B
    Posit Aware; 1998; 9(5):54. PubMed ID: 11365897
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Hydroxyurea may enhance effectiveness of anti-HIV regimens presently in use.
    Murphy MJ
    Fac Notes (New Orleans La); 1998; 10(2):1-2. PubMed ID: 11365124
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of didanosine, stavudine, and hydroxyurea therapy on apoptosis in CD45RA+ and CD45RO+ T lymphocyte subpopulations.
    Nokta M; Rossero R; Nichols J; Rosenbaum M; Pollard RB
    AIDS Res Hum Retroviruses; 1999 Feb; 15(3):255-64. PubMed ID: 10052756
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immunosuppressive drugs as an adjuvant to HIV treatment.
    Fumero E; García F; Gatell JM
    J Antimicrob Chemother; 2004 Mar; 53(3):415-7. PubMed ID: 14963070
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Use of hydroxyurea in heavily pretreated patients with HIV infection.
    Hermans P; De Wit S; Sommereijns B; O'Doherty E; Clumeck N
    Antivir Ther; 1999; 4 Suppl 3():19-22. PubMed ID: 16021867
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Hydroxychloroquine, hydroxyurea and didanosine as initial therapy for HIV-infected patients with low viral load: safety, efficacy and resistance profile after 144 weeks.
    Paton NI; Aboulhab J
    HIV Med; 2005 Jan; 6(1):13-20. PubMed ID: 15670247
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Hydroxyurea in the treatment of Churg-Strauss syndrome.
    Lee RU; Stevenson DD
    J Allergy Clin Immunol; 2009 Nov; 124(5):1110-1. PubMed ID: 19703710
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.